From Fatal to Functional: GPNMB CAR-T Therapy Eradicates Glioblastoma

A groundbreaking dual-target CAR-T therapy targeting GPNMB has achieved complete tumor eradication in preclinical glioblastoma models, overcoming the immune microenvironment that previously ensured 90% recurrence. This breakthrough signals a transition from reactive cancer management to functional cure, potentially saving 12,000 U.S. patients annually and reducing lifetime costs by $1.2 million per case.